China Journal of Leprosy and Skin Diseases ›› 2026, Vol. 42 ›› Issue (6): 444-446.doi: 10.12144/zgmfskin202606444

• Case Reports • Previous Articles     Next Articles

Deucravacitinib for the treatment of erythrodermic psoriasis: a case report

WEI Ting1,2,3, ZHANG Fan1,2, ZHANG Yuan1,2, TIAN Hongqing1,2   

  1. 1 Dermatology Hospital Affiliated of Shandong First Medical University, Jinan 250022, China; 2 Shandong Provincial Institute of Dermatology and Venereology, Shandong Academy of Medical Sciences, Jinan 250022, China; 3 Taian Central Hospital, Taian 271000, China
  • Online:2026-06-15 Published:2026-06-04

Abstract: We report a case of successful treatment with deucravacitinib in a patient with erythrodermic psoriasis. The patient was a 75-year-old male. He had experienced recurrent erythema, plaques, and desquamation on the trunk and extremities for 8 years, with generalized involvement for 5 years. The condition relapsed 2 months ago. He had been treated with oral cyclosporine intermittently, but the effect was unsatisfactory. He was given 6 mg of deucravacitinib orally once daily. Four weeks later, he returned for a follow-up visit, and the diffuse dark erythema and desquamation over the entire body had subsided. He is still under follow-up.

Key words: erythrodermic psoriasis, deucravacitinib, JAK inhibitors